Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:982 (12 May), doi:10.1136/bmj.39202.399942.AD
Scott M Grundy, professor
Center for Human Nutrition, Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9052, USA
scott.grundy@utsouthwestern.edu
Women in western countries are more likely to die from heart disease than from cancer. Scott M Grundy argues that the risks make preventive treatment essential, but Malcolm Kendrick believes the evidence of benefit is not strong enough
| The first 150 words of the full text of this article appear below. |
Primary and secondary trials show that cholesterol lowering drugs reduce the risk of cardiovascular disease events in men.1 2 Secondary prevention trials in women with established cardiovascular disease also show a reduction in risk.3 4 5 Meta-analyses also show that when all women with or without cardiovascular disease are combined, cholesterol lowering treatment produces benefit.6 7
Some investigators nevertheless argue that women without cardiovascular disease should not be given cholesterol lowering drugs because of insufficient evidence from primary prevention trials in women.8 They speculate that women with and without cardiovascular disease respond differently to the drugs; if true, women may not respond to treatment even when they have the same level of risk as men who do benefit.1 2 This speculation discounts prospective studies showing that raised cholesterol concentration is a major risk factor for first heart attack in both men and women.9
The pathological basis for a difference in response to cholesterol lowering therapy
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+